Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | ATM | Q13315 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14079936 | 0.81 | KDM4E (0.31) | ALDH1A1TDP1KDM4EATM | |
| SCHEMBL22301098 | 0.79 | ALDH1A1 (0.30) | ALDH1A1TDP1 | |
| SCHEMBL13151100 | 0.79 | ALDH1A1 (0.30) | ALDH1A1TDP1 | |
| SCHEMBL162905 | 0.78 | TDP1 (0.39) | ALDH1A1TDP1KDM4EATM | |
| SCHEMBL10072131 | 0.76 | KMT2A (0.31) | KDM4EATM | |
| SCHEMBL8258938 | 0.76 | ALDH1A1 (0.37) | ALDH1A1KDM4EATM | |
| Hydrochloric Acid SCHEMBL5560964 | 0.76 | TDP1 (0.38) | ALDH1A1TDP1KDM4EATM | |
| SCHEMBL22828145 | 0.75 | LMNA (0.30) | — | |
| SCHEMBL12084014 | 0.74 | ALDH1A1 (0.35) | ALDH1A1TDP1TRPA1 | |
| SCHEMBL21706286 | 0.74 | TDP1 (0.43) | ALDH1A1TDP1KDM4EATM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11760761-B2 | Methods and compositions for targeting PD-L1 | ALIGOS THERAPEUTICS, INC. (US) | 2023-09-19 | — | — | US | disclosed |
| US-20230212212-A1 | PROCESSES FOR PREPARING OLIGONUCLEOTIDES | SHANGHAI STA PHARMACEUTICAL R&D CO., LTD. (CN) | 2023-07-06 | — | — | US | disclosed |
| US-8138361-B2 | C-10 carbamates of taxanes | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2012-03-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11760761-B2 | Methods and compositions for targeting PD-L1 | CD274, PDCD1LG2, PDCD1 | ALDH1A1 301/4885TDP1 2926/4885TRPA1 4754/4885 |
| US-20230212212-A1 | PROCESSES FOR PREPARING OLIGONUCLEOTIDES | XRN2, UPF1, NSUN2 | ALDH1A1 2892/4885TDP1 182/4885TRPA1 3186/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.